NFKB1 and Alzheimer disease: In 2020, Nakano and coworkers observed that intraventricular administrated BM-MSCs decreased nuclear factor kappa B (NF-κB) expression, while improving microRNA (miR)-146a levels in the hippocampus in a mouse model of AD [105].